An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients
Information source: Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Psoriasis
Intervention: etanercept (Drug)
Phase: N/A
Status: Enrolling by invitation
Sponsored by: Universitaire Ziekenhuizen Leuven
Summary
The purpose of this study is to investigate the association between trough serum levels of
etanercept, antibodies towards etanercept and its effectiveness in psoriasis patients.
Clinical Details
Official title: Intermittent Versus Continuous Treatment: an Observational Monocentric Study Investigating the Association Between Trough Levels of Enbrel and Therapy Regimen
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: trough serum etanercept concentrationanti-etanercept serum concentration
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age from 18 years on, male or female
- Established diagnosis of psoriasis
- Etanercept either on monotherapy or in combination with acitretin (Neotigason®),
given according to the current EU SmPC including the safety measures.
- Patients who give informed consent for this study
Locations and Contacts
Additional Information
Starting date: January 2015
Last updated: January 8, 2015
|